With a new year and decade underway, the World Health Organization has unveiled a list of urgent, global health challenges, developed with input from experts around the world. This list includes drug resistance and access to lifesaving medicines as grave challenges putting lives, livelihoods and economies in jeopardy.
Speaking of the challenges, Dr Tedros Adhanom Ghebreyesus, WHO Director-General, said “With the deadline for the 2030 Sustainable Development Goals quickly approaching, the United Nations General Assembly has underscored that the next 10 years must be the ‘decade of action.’”
What is GARDP doing about these challenges? To tackle the urgent issues of drug resistance and access to antibiotics, GARDP is working with more than 50 partners in 20 countries – including the WHO – to develop new and improved treatments for drug-resistant infections. GARDP is working with these partners to ensure sustainable access to treatments, promoting responsible use and affordability to all in need.
GARDP’s research and development efforts focus on urgently needed treatments for bacteria on the WHO priority pathogens list, as well as for people disproportionately affected by drug resistance, including babies and children, people with sexually-transmitted diseases and hospitalized adults. GARDP is addressing critically underfunded and unfilled gaps in the development of antibiotics by tracking, evaluating and contributing where others are not.
GARDP’s 5BY25 campaign seeks to deliver five new treatments by 2025 to tackle the drug-resistant infections that pose the greatest threat to global health and economic security. GARDP is seeking €500 million to develop these treatments. This work can only be done together.
If we act now, collectively and with urgency, we can prevent a post-antibiotic era. Join GARDP in this important endeavour to deliver five urgently needed treatments by 2025.